CNOB/ChrR6, a new prodrug enzyme cancer chemotherapy
暂无分享,去创建一个
Christopher H Contag | Jianghong Rao | C. Contag | M. Bachmann | S. Thorne | A. Matin | J. Rao | Y. Barak | Michael H Bachmann | Michael H. Bachmann | Yoram Barak | A Matin | Steve H Thorne | Wenchuan Liang | A. Matin | Wenchuan Liang
[1] C. Springer,et al. Viral vectors for gene-directed enzyme prodrug therapy. , 2006, Current gene therapy.
[2] E. Cadenas,et al. Antioxidant and prooxidant functions of DT-diaphorase in quinone metabolism. , 1995, Biochemical pharmacology.
[3] S. Thorne. Strategies to achieve systemic delivery of therapeutic cells and microbes to tumors , 2007, Expert opinion on biological therapy.
[4] O. Greco,et al. Prodrugs in genetic chemoradiotherapy. , 2003, Current pharmaceutical design.
[5] G. Prendergast. Molecular cancer therapeutics : strategies for drug discovery and development , 2005 .
[6] J. Brown,et al. Exploiting tumour hypoxia in cancer treatment , 2004, Nature Reviews Cancer.
[7] Nico P E Vermeulen,et al. Enzyme-Catalyzed Activation of Anticancer Prodrugs , 2004, Pharmacological Reviews.
[8] K. Bagshawe. Antibody-directed enzyme prodrug therapy (ADEPT) for cancer , 2006, Expert review of anticancer therapy.
[9] A. Matin,et al. Analysis of Novel Soluble Chromate and Uranyl Reductases and Generation of an Improved Enzyme by Directed Evolution , 2006, Applied and Environmental Microbiology.
[10] A. Reynolds,et al. Nanoparticle-mediated gene delivery to tumour neovasculature. , 2003, Trends in Molecular Medicine.
[11] A. Charbit,et al. High efficiency transformation of Salmonella typhimurium and Salmonella typhi by electroporation , 1990, Molecular and General Genetics MGG.
[12] Campbell W. Gourlay,et al. The actin cytoskeleton: a key regulator of apoptosis and ageing? , 2005, Nature Reviews Molecular Cell Biology.
[13] Meng Yang,et al. Monotherapy with a tumor-targeting mutant of Salmonella typhimurium cures orthotopic metastatic mouse models of human prostate cancer , 2007, Proceedings of the National Academy of Sciences.
[14] W. Denny. Nitroreductase-based GDEPT. , 2002, Current pharmaceutical design.
[15] D. Kerr,et al. Virus-directed, enzyme prodrug therapy with nitroimidazole reductase: a phase I and pharmacokinetic study of its prodrug, CB1954. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[16] F. Friedlos,et al. A new cytotoxic, DNA interstrand crosslinking agent, 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide, is formed from 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by a nitroreductase enzyme in Walker carcinoma cells. , 1988, Biochemical pharmacology.
[17] C. Contag,et al. Synergistic Antitumor Effects of Immune Cell-Viral Biotherapy , 2006, Science.
[18] G. Tozer,et al. From bench to bedside for gene-directed enzyme prodrug therapy of cancer. , 2005, Anti-cancer drugs.
[19] D. Largaespada,et al. RNA as a source of transposase for Sleeping Beauty-mediated gene insertion and expression in somatic cells and tissues. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.
[20] A. Matin,et al. Chromate-Reducing Properties of Soluble Flavoproteins from Pseudomonas putida and Escherichia coli , 2004, Applied and Environmental Microbiology.
[21] Shiuan Chen,et al. Quinone reductase-mediated nitro-reduction: clinical applications. , 2004, Methods in enzymology.
[22] I. Tannock,et al. Drug penetration in solid tumours , 2006, Nature Reviews Cancer.
[23] M. Bednarski,et al. Tumor Regression by Targeted Gene Delivery to the Neovasculature , 2002, Science.
[24] A. Sartorelli,et al. Bioactivation and resistance to mitomycin C. , 2004, Methods in enzymology.
[25] David F Ackerley,et al. Enzyme improvement in the absence of structural knowledge: a novel statistical approach , 2008, The ISME Journal.
[26] A. Matin,et al. ChrR, a Soluble Quinone Reductase of Pseudomonas putida That Defends against H2O2* , 2005, Journal of Biological Chemistry.
[27] C. Contag,et al. New enzyme for reductive cancer chemotherapy, YieF, and its improvement by directed evolution , 2006, Molecular Cancer Therapeutics.